The notices it replaced
- Reissues: PAS-18-063 HIV/AIDS High Priority Drug Abuse Research (R01 Clinical Trial Optional)
- 2 steps back: PAS-16-018 HIV/AIDS High Priority Drug Abuse Research (R01)
Replaced by RFA-DA-22-040.
Who won it before
34 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $21,832,050 in first-year total cost, median $656,487.
Most frequent study sections
- NeuroAIDS and other End-Organ Diseases Study Section[NAED]8
- Population and Public Health Approaches to HIV/AIDS Study Section[PPAH]5
- Behavioral and Social Science Approaches to Preventing HIV/AIDS Study Section[BSPH]4
- Special Emphasis Panel[ZRG1 AARR-N (02)]3
- HIV Comorbidities and Clinical Studies Study Section[HCCS]2
Most frequent institutions
- JOHNS HOPKINS UNIVERSITY3
- YALE UNIVERSITY3
- TEMPLE UNIV OF THE COMMONWEALTH2
- UNIVERSITY OF BRITISH COLUMBIA2
- UNIVERSITY OF CALIFORNIA, SAN FRANCISCO2
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2022 | Expanding Medication Assisted Therapies in Central Asia1R01DA054851-01A1 | ALTICE, FREDERICK LEWISMADDEN, LYNN | YALE UNIVERSITY, CT | $625,373 | PPAH |
| 2021 | Impact of a novel HIV peer navigationand overdose prevention intervention on engagement in the HIV prevention and treatment cascade.1R01DA053184-01A1 | SHERMAN, SUSAN G. | JOHNS HOPKINS UNIVERSITY, MD | $794,472 | ZRG1 |
| 2021 | Risk Factors for AIDS among Persons Who Inject Drugs: HIV and COVID-192R01DA003574-37A1 | DES JARLAIS, DON CMCKNIGHT, COURTNEY | NEW YORK UNIVERSITY, NY | $792,422 | PPAH |
| 2021 | Stigma and Substance Use as Barriers to PrEP Linkage, Uptake, Adherence, and Persistence among BMSM1R01DA053168-01 | EATON, LISA A | UNIVERSITY OF CONNECTICUT STORRS, CT | $622,614 | HIBI |
| 2021 | Modulation of OPRM1 alternative splicing by morphine and HIV-1 Nef1R01DA052284-01A1 | CHANG, SULIE L.SARIYER, ILKER KUDRET | TEMPLE UNIV OF THE COMMONWEALTH, PA | $358,742 | HVCD |
| 2021 | The ION+EMI Study: Intermittent Oral Naltrexone enhanced with an Ecological Momentary Intervention for Methamphetamine-using MSM1R01DA053171-01A1 | SANTOS, GLENN-MILO | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $329,820 | HIBI |
| 2020 | Cocaine use, viral suppression and precursors of stroke in HIV infection1R01DA049648-01A1 | RILEY, ELISE D. | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $805,697 | HCCS |
| 2020 | A geospatial analysis of hotspots and targeted injection settings pilot intervention for HIV prevention among people who inject drugs in Baltimore, Maryland1R01DA050470-01A1 | LATKIN, CARL A | JOHNS HOPKINS UNIVERSITY, MD | $784,526 | PPAH |
| 2020 | Resubmission: Multilevel Strategies & Tailored HIV Prevention & Care for Young Couples who use Alcohol & Other Drugs Across Cape Town1R01DA049612-01A1 | BROWNE, FELICIA AMIRACARNEY, TARAWECHSBERG, WENDEE M | RESEARCH TRIANGLE INSTITUTE, NC | $732,304 | PPAH |
| 2020 | Impacts of structural and system-level interventions on HIV/STI and overdose epidemics among SWs2R01DA028648-11 | GOLDENBERG, SHIRA MIRIAMSHANNON, KATE | UNIVERSITY OF BRITISH COLUMBIA, BC | $538,742 | PPAH |
| 2020 | HIV-1 Neurotoxicity: Mechanism & Modulation by Cannabinoids2R01DA007304-28A1 | THAYER, STANLEY A | UNIVERSITY OF MINNESOTA, MN | $457,086 | HVCD |
| 2019 | Effects of mu-opiate receptor engagement on microbial translocation and residual immune activation in HIV-infected, ART suppressed opioid use disorder patents initiating medication-assisted treatment1R01DA048728-01 · under PAS-18-063 | METZGER, DAVID SMONTANER, LUIS J | WISTAR INSTITUTE, PA | $1,248,932 | HCCS |
| 2019 | Effects of Mu-opiate receptor engagement on the persistence of HIV-associated activation and viral reservoirs in individuals receiving medication assisted treatment for opioid use disorder1R01DA049666-01 | MONTANER, LUIS J | WISTAR INSTITUTE, PA | $827,942 | HIVD |
| 2019 | Elimination of HCV and related liver disease among HIV-infected and -uninfected people who inject drugs1R01DA048063-01 · under PAS-18-063 | MEHTA, SHRUTI HTHOMAS, DAVID L | JOHNS HOPKINS UNIVERSITY, MD | $727,804 | ZRG1 |
| 2018 | Effects of State Laws to Reduce Opioid Diversion on Transitions to Injection Drug Use and HIV/HCV Transmission1R01DA044971-01A1 · under PAS-16-018 | DICKSON-GOMEZ, JULIA B | MEDICAL COLLEGE OF WISCONSIN, WI | $652,675 | ZRG1 |
| 2018 | The impact of naltrexone treatment on opioid-induced immune and viral dysregulation during HIV-infection1R01DA046229-01A1 · under PAS-18-063 | LANCIONI, CHRISTINA LOUISE | OREGON HEALTH & SCIENCE UNIVERSITY, OR | $415,765 | NAED |
| 2018 | Role of miRNAs in Methamphetamine/HIV-mediated Immune Activation1R01DA045568-01A1 · under PAS-16-018 | HO, WENZHE | TEMPLE UNIV OF THE COMMONWEALTH, PA | $396,250 | ZRG1 |
| 2018 | Immunomodulation of nicotine in HIV-1Tg rat brain1R01DA046258-01 · under PAS-16-018 | CHANG, SULIE L.LI, MING D | SETON HALL UNIVERSITY, NJ | $347,750 | NAED |
| 2017 | A Multi-site Multi-Setting RCT of Integrated HIV Prevention and HCV Care for PWID1R01DA045713-01 · under PAS-16-018 | BRUNEAU, JULIEFEASTER, DANIEL JMETSCH, LISA R | COLUMBIA UNIVERSITY HEALTH SCIENCES, NY | $1,322,957 | ZDA1 |
| 2017 | Expanding Medication Assisted Therapy in Ukraine (ExMAT)2R01DA033679-06 · under PAS-16-018 | ALTICE, FREDERICK LEWIS | YALE UNIVERSITY, CT | $769,707 | BSPH |
| 2017 | Buprenorphine treatment at syringe exchanges to reduce opioid misuse and HIV risk1R01DA044878-01 · under PAS-16-018 | FOX, AARON D | ALBERT EINSTEIN COLLEGE OF MEDICINE, INC, NY | $721,387 | BSPH |
| 2017 | Integrated Behavioral Activation and HIV Risk Reduction Counseling for MSM with Stimulant Abuse1R01DA042805-01A1 · under PAS-16-018 | MIMIAGA, MATTHEW JAMESSAFREN, STEVEN A | BROWN UNIVERSITY, RI | $714,427 | ZDA1 |
| 2017 | Testing an integrated bio-behavioral primary HIV prevention intervention among high-risk people who use drugs1R01DA044867-01 · under PAS-16-018 | COPENHAVER, MICHAEL | UNIVERSITY OF CONNECTICUT STORRS, CT | $690,524 | BSPH |
| 2017 | HIV/COCAINE NEUROTOXICITY IN FEMALES2R01DA013137-16 · under PAS-16-018 | BOOZE, ROSEMARIE MMACTUTUS, CHARLES F. | UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA, SC | $600,321 | ZRG1 |
| 2017 | Impacts of universal access to HIV/AIDS care among HIV+ injection drug users2U01DA021525-11 · under PAS-16-018 | MILLOY, M-J | UNIVERSITY OF BRITISH COLUMBIA, BC | $541,273 | ZRG1 |
| 2017 | Bivalent Ligands as Chemical Probes to Study Opioid Abuse-enhanced HIV Infection1R01DA044855-01 · under PAS-16-018 | HAUSER, KURT FZHANG, YAN | VIRGINIA COMMONWEALTH UNIVERSITY, VA | $507,931 | NAED |
| 2017 | Primary role of Golgi stress in anti-HIV drug and alcohol abuse-induced hepatotoxicity1R01DA042632-01A1 · under PAS-16-018 | JI, CHENG | UNIVERSITY OF SOUTHERN CALIFORNIA, CA | $412,500 | NAED |
| 2017 | An ethno-epidemiological study to advance HIV prevention and treatment for PWUD1R01DA043408-01 · under PAS-16-018 | MCNEIL, RYANSMALL, WILL | SIMON FRASER UNIVERSITY, BC | $325,817 | BSPH |
| 2016 | Impact of smoking and its cessation on systemic and airway immune activation1R01DA042685-01 · under PAS-16-018 | LIN, NINA H.SPIRA, AVRUM E | BOSTON MEDICAL CENTER, MA | $827,665 | NAED |
| 2016 | OMICs to define impact of cocaine on immunity and HIV persistence in treated HIV infection1R01DA042712-01 · under PAS-16-018 | SEKALY, RAFICK PIERRE | CASE WESTERN RESERVE UNIVERSITY, OH | $717,500 | NAED |
| 2016 | Nanotechnology Based Gene Editing to Eradicate HIV Brain Reservoir in Drug Abusers1R01DA042706-01 · under PAS-16-018 | KHALILI, KAMELNAIR, MADHAVAN P. | FLORIDA INTERNATIONAL UNIVERSITY, FL | $680,840 | NAED |
| 2016 | Understanding the Role of Cognitive Dysfunction in the Treatment of Nicotine Dependence among HIV-Infected Smokers1R01DA042682-01 · under PAS-16-018 | ASHARE, REBECCA | UNIVERSITY OF PENNSYLVANIA, PA | $660,298 | BSCH |
| 2016 | Methylome-wide and mQTL analysis of HIV progression in the context of cocaine use1R01DA042691-01 · under PAS-16-018 | XU, KE | YALE UNIVERSITY, CT | $468,553 | ZRG1 |
| 2016 | Extracellular Vesicles and and HIV/cocaine associated cardiopulmonary dysfunction1R01DA042715-01 · under PAS-16-018 | DHILLON, NAVNEET KAUR | UNIVERSITY OF KANSAS MEDICAL CENTER, KS | $411,434 | NAED |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.